Leptomeningeal metastases (LM) currently lack standardization with respect to response
assessment. A Response Assessment in Neuro-Oncology (RANO) working group with …

Leptomeningeal metastasis is an uncommon and typically late complication of cancer with a
poor prognosis and limited treatment options. Diagnosis is often challenging, with …

These EANO–ESMO joint recommendations for the diagnosis and treatment of
leptomeningeal metastasis (LM) from solid cancers represent the first European guideline …

Leptomeningeal disease (LMD) is a common complication from solid tumor malignancies
with a poor prognosis and limited treatment options. We present a single arm Phase II study …

Leptomeningeal metastasis (LM) results from metastatic spread of cancer to the
leptomeninges, giving rise to central nervous system dysfunction. Breast cancer, lung …

Leptomeningeal carcinomatosis occurs in approximately 5% of patients with cancer. This
disorder is being diagnosed with increasing frequency as patients live longer and as neuro …

An increasing fraction of patients with metastatic cancer develop leptomeningeal
dissemination of disease (LMD), and survival is dismal,–. We conducted a single-arm, phase …

Standard treatment for neoplastic meningitis requires frequent intrathecal (IT) injections of
chemotherapy and is only modestly effective. DepoCyt is a sustained-release formulation of …

Abstract Background The EANO ESMO guidelines have proposed a classification of
leptomeningeal metastases (LM) from solid cancers based on clinical, magnetic resonance …

Leptomeningeal metastasis is a fatal manifestation seen in advanced cancer patients. Its
incidence is increasing, reaching 3.8% in molecularly unselected non-small cell lung cancer …